Overview

Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).
Phase:
Phase 2
Details
Lead Sponsor:
Olfred Hansen
Collaborators:
Aalborg Universitetshospital
Aalborg University Hospital
Aarhus University Hospital
Copenhagen University Hospital at Herlev
Naestved Hospital
Odense University Hospital
Rigshospitalet, Denmark
Treatments:
Erlotinib Hydrochloride